Vitamin D dependency: replacement therapy with calcitriol?
Nine patients with vitamin D-dependency type I were studied. We observed that treatment with large doses of vitamin D altered the phenotypic expression of the disease, thus making a delayed diagnosis difficult. At the time of entry, eight children had hypocalcemia, and seven had hypophosphatemia. Elevated serum immunoreactive parathyroid hormone and low (less than 3 SD from control mean) 1 alpha,25-dihydroxyvitamin D values were constant findings, with no vitamin D deficiency. Despite the elevated serum iPTH, three children had normal urinary phosphate excretion and five had normal urinary cAMP excretion. In the five children tested before treatment, there was no significant change in renal phosphate excretion during an acute parathyroid hormone infusion, although in all a significant rise of urinary cAMP occured. Treatment with calcitriol (0.25 to 2 microgram/day) returned all the biochemical values to normal within four months. In two patients, both supplemented with vitamin D, histomorphometric analysis of iliac crest biopsies revealed severe osteomalacia. After nine and ten months of treatment with calcitriol, there was histologic evidence for improvement of bone mineralization. Since calcitriol requirements may vary during the course of treatment, careful monitoring of biochemical variables is essential.
D000293:Adolescent; D000328:Adult; D001774:Blood Chemical Analysis; D002117:Calcitriol / Q000031:analogs & derivatives*; D002648:Child; D002675:Child, Preschool; D053493:Cholestanetriol 26-Monooxygenase; D002986:Clinical Trials as Topic; D000242:Cyclic AMP / Q000652:urine; D004100:Dihydroxycholecalciferols / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006887:Hydroxycholecalciferols / Q000627:therapeutic use*; D006996:Hypocalcemia / Q000139:chemically induced; D007015:Hypophosphatemia, Familial / Q000188:drug therapy*; D007275:Injections, Intravenous; D008137:Longitudinal Studies; D008297:Male; D010281:Parathyroid Hormone / Q000097:blood / Q000652:urine; D010710:Phosphates / Q000097:blood / Q000652:urine; D013250:Steroid Hydroxylases / Q000097:blood; D019966:Substance-Related Disorders / Q000175:diagnosis*; D014807:Vitamin D / Q000009:adverse effects / Q000627:therapeutic use*
D004100:Dihydroxycholecalciferols; D006887:Hydroxycholecalciferols; D010281:Parathyroid Hormone; D010710:Phosphates; D014807:Vitamin D; C026947:1,25-dihydroxyvitamin D3-26,23-lactone; D000242:Cyclic AMP; D013250:Steroid Hydroxylases; C506831:CYP27A1 protein, human; D053493:Cholestanetriol 26-Monooxygenase; D002117:Calcitriol